dysfunction is progressive, many type 2diabetic patients eventually require insu-lin as primary therapy to achieve glycemicgoals (5,6). Glucose control in this popu-lation remains inadequate, as averageHbA 1cvalues reported in most epidemio - logic studies are well above 8% as com-pared with normal levels /H110216%, despite the availability of a number of therapeuticagents (7,8). AC2993 (synthetic exendin-4; ex-